Civica Rx began construction in early 2021 on a $124.5 million pharmaceutical manufacturing center in Petersburg, Va. Created in collaboration with Phlow Corp., the 120,000-sf plant will produce sterile injectables for the treatment of COVID-19, emergency room and intensive-care unit treatments, surgeries, and other serious conditions. The facility will feature steam sterilization capabilities, disposable technologies, and advanced automation systems for visual inspection and packaging. Next-generation filling lines will produce 90 million vials and 50 million syringes per year, and temperature-controlled warehouse space will ensure the integrity of raw materials and finished medications. Operations at the site will begin within three years.
The project is part of a $354 million contract awarded by the U.S. Biomedical Advanced Research and Development Authority to Civica Rx, Phlow Corp., AMPAC Fine Chemicals, and Virginia Commonwealth University's Medicines for All Institute to ensure a safe, stable, and affordable supply of essential medicines for U.S patients. Civica's role is to produce finished dosage medications for the U.S. Strategic National Stockpile and Civica member hospitals.
